Outpatient Oncology Infusion Market Analysis

Outpatient Oncology Infusion Market Analysis

Based on product, the infusion pump segment accounted for around 50% market share in 2021 owing to the growing cancers instances across the globe coupled with the growing use of infusion pumps for cancer therapy. For instance, as per World Health Organization (WHO), in 2018, cancer was estimated to be the second most prominent cause of death globally and is responsible for about 9.6 million deaths. Furthermore, cancer patients require continuous delivery of chemotherapy, which can be accomplished with the use of infusion pumps.
 

Infusion pumps are used to deliver fluids precisely and consistently such as medicines, antibiotics, and nutrients in a patient's body. Also, infusion pumps such as ambulatory chemotherapy pumps, and implantable pumps, are useful for managing cancer in hospitals, outpatient care centers, and home care settings. Such benefits associated with this product will spur the segmental as well as outpatient oncology infusion market growth over the forecast period.
 

By application, the lung cancer segment accounted for around USD 6.7 billion market size in 2021. The factors such as rising occurrences of lung cancer and rising level of geriatric population along with changing lifestyles with high smoking habits, further results in a large pool of carcinoma lung population that fosters demand for outpatient oncology infusion therapy. Thus, augmenting market growth.
 

For instance, according to the American Cancer Society 2022, lung cancer is the leading cause of death in both men and women, accounting for over 25% of all cancer-related deaths.
 

Moreover, the surging introduction of targeted therapies for the treatment of lung cancer will propel the outpatient oncology infusion market during the analysis timeframe. For instance, in September 2018, Pfizer Inc., received the U.S. FDA approval for VIZIMPRO (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
 

Based on therapy, The chemotherapy segment accounted for over 17% market share in 2021 and is estimated to expand at a substantial pace over the analysis timeframe due to the advantages offered by the infusion treatment in chemotherapy coupled with the increasing demand for outpatient oncology infusion chemotherapy for the treatment of cancer diseases. Doctors highly recommend infusion therapy for cancer patients because it permits specifically designed medicines to permeate the body that inhibit cellular mitosis. As per the recent research, the potential advantages of treating cancer at the outpatient center through infusion therapy include relieving distress from symptoms, reducing the risk of complications, and cost-effective than hospital-based care.
 

Outpatient infusion intravenous chemotherapy allows patients to better manage their symptoms and adherence to chemotherapy schedules. Moreover, novel chemotherapy infusion systems deliver improved quality of life and allow precise monitoring of the patient through connected devices. Hence, the several benefits provided by chemotherapy in cancer patients have stimulated outpatient oncology infusion industry growth.
 

Based on mode, The intravenous (IV) segment accounted for around 31% of market share in 2021 owing to the benefits provided by intravenous infusion therapy treatment. This intravenous infusion of antibiotic drugs is highly used to treat disorders that do not respond to oral therapeutics, thereby significantly driving the demand for outpatient oncology infusion and will spur the overall market expansion.
 

Also, intravenous is one of the common routes of administration for chemotherapy and immunotherapy process. Furthermore, intravenous route delivers medications quickly and replace fluid throughout the body as they are introduced directly into the circulatory system. For this reason, the IV route is usually recommended in emergencies or when prompt action is desired.
 

North America outpatient oncology infusion industry accounted for a significant share in 2021 and is anticipated to expand at a notable pace to reach around USD 68 billion by 2030 owing to various factors such as the favorable government initiatives, increasing cancer patient and rising geriatric population among others.
 

For instance, as per the Population Reference Bureau, the number of Americans aged 65 and more is expected to double by 2060, from 52 million in 2018. The rising prevalence of chronic diseases such as cancer is also aided market expansion. For instance, according to the National Cancer Institute, in 2020, in the U.S. around 1,806,590 cancer cases were identified.
 

Besides, increasing product approval in the North America also contributes to regional market growth. For instance, in May 2021, Amgen received U.S. Food and Drug Administration (FDA) approval for LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C- metastatic non-small cell lung cancer (NSCLC). This approval aided the company to drive product sales and bolster its industrial position in North America outpatient oncology infusion industry.